Literature DB >> 23700264

A study of tropomyosin's role in cardiac function and disease using thin-filament reconstituted myocardium.

Fan Bai1, Li Wang, Masataka Kawai.   

Abstract

Tropomyosin (Tm) is the key regulatory component of the thin-filament and plays a central role in the cardiac muscle's cooperative activation mechanism. Many mutations of cardiac Tm are related to hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and left ventricular noncompaction (LVNC). Using the thin-filament extraction/reconstitution technique, we are able to incorporate various Tm mutants and protein isoforms into a muscle fiber environment to study their roles in Ca(2+) regulation, cross-bridge kinetics, and force generation. The thin-filament reconstitution technique poses several advantages compared to other in vitro and in vivo methods: (1) Tm mutants and isoforms are placed into the real muscle fiber environment to exhibit their effect on a level much higher than simple protein complexes; (2) only the primary and immediate effects of Tm mutants are studied in the thin-filament reconstituted myocardium; (3) lethal mutants of Tm can be studied without causing a problem; and (4) inexpensive. In transgenic models, various secondary effects (myocyte disarray, ECM fibrosis, altered protein phosphorylation levels, etc.) also affect the performance of the myocardium, making it very difficult to isolate the primary effect of the mutation. Our studies on Tm have demonstrated that: (1) Tm positively enhances the hydrophobic interaction between actin and myosin in the "closed state", which in turn enhances the isometric tension; (2) Tm's seven periodical repeats carry distinct functions, with the 3rd period being essential for the tension enhancement; (3) Tm mutants lead to HCM by impairing the relaxation on one hand, and lead to DCM by over inhibition of the AM interaction on the other hand. Ca(2+) sensitivity is affected by inorganic phosphate, ionic strength, and phosphorylation of constituent proteins; hence it may not be the primary cause of the pathogenesis. Here, we review our current knowledge regarding Tm's effect on the actomyosin interaction and the early molecular pathogenesis of Tm mutation related to HCM, DCM, and LVNC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23700264      PMCID: PMC3849125          DOI: 10.1007/s10974-013-9343-z

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  144 in total

1.  Effect of phosphorylation on the interaction and functional properties of rabbit striated muscle alpha alpha-tropomyosin.

Authors:  D H Heeley; M H Watson; A S Mak; P Dubord; L B Smillie
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

2.  Tropomyosin coiled-coil interactions: evidence for an unstaggered structure.

Authors:  A D McLachlan; M Stewart
Journal:  J Mol Biol       Date:  1975-10-25       Impact factor: 5.469

3.  The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy.

Authors:  V V Michels; P P Moll; F A Miller; A J Tajik; J S Chu; D J Driscoll; J C Burnett; R J Rodeheffer; J H Chesebro; H D Tazelaar
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

Review 4.  The actomyosin interaction and its control by tropomyosin.

Authors:  K C Holmes
Journal:  Biophys J       Date:  1995-04       Impact factor: 4.033

Review 5.  Regulation of cardiac contractile function by troponin I phosphorylation.

Authors:  Joanne Layland; R John Solaro; Ajay M Shah
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

6.  Tropomyosin dephosphorylation results in compensated cardiac hypertrophy.

Authors:  Emily M Schulz; Richard N Correll; Hajer N Sheikh; Marco S Lofrano-Alves; Patti L Engel; Gilbert Newman; Jo El J Schultz; Jeffery D Molkentin; Beata M Wolska; R John Solaro; David F Wieczorek
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

7.  Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Erik G Ellsworth; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

Review 8.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

9.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984.

Authors:  M B Codd; D D Sugrue; B J Gersh; L J Melton
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

10.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.

Authors:  Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin
Journal:  J Card Fail       Date:  2009-03       Impact factor: 5.712

View more
  24 in total

Review 1.  Modelling sarcomeric cardiomyopathies with human cardiomyocytes derived from induced pluripotent stem cells.

Authors:  Lorenzo R Sewanan; Stuart G Campbell
Journal:  J Physiol       Date:  2019-02-06       Impact factor: 5.182

Review 2.  A new twist on tropomyosin binding to actin filaments: perspectives on thin filament function, assembly and biomechanics.

Authors:  William Lehman; Michael J Rynkiewicz; Jeffrey R Moore
Journal:  J Muscle Res Cell Motil       Date:  2019-02-15       Impact factor: 2.698

3.  The Effect of Tropomyosin Mutations on Actin-Tropomyosin Binding: In Search of Lost Time.

Authors:  William Lehman; Jeffrey R Moore; Stuart G Campbell; Michael J Rynkiewicz
Journal:  Biophys J       Date:  2019-05-13       Impact factor: 4.033

4.  Using baculovirus/insect cell expressed recombinant actin to study the molecular pathogenesis of HCM caused by actin mutation A331P.

Authors:  Fan Bai; Hannah M Caster; Peter A Rubenstein; John F Dawson; Masataka Kawai
Journal:  J Mol Cell Cardiol       Date:  2014-04-30       Impact factor: 5.000

5.  Investigating the effects of tropomyosin mutations on its flexibility and interactions with filamentous actin using molecular dynamics simulation.

Authors:  Wenjun Zheng; Sarah E Hitchcock-DeGregori; Bipasha Barua
Journal:  J Muscle Res Cell Motil       Date:  2016-07-04       Impact factor: 2.698

Review 6.  Cardiomyopathy-associated mutations in tropomyosin differently affect actin-myosin interaction at single-molecule and ensemble levels.

Authors:  Galina V Kopylova; Daniil V Shchepkin; Salavat R Nabiev; Alexander M Matyushenko; Natalia A Koubassova; Dmitrii I Levitsky; Sergey Y Bershitsky
Journal:  J Muscle Res Cell Motil       Date:  2019-10-23       Impact factor: 2.698

7.  A Stochastic Multiscale Model of Cardiac Thin Filament Activation Using Brownian-Langevin Dynamics.

Authors:  Yasser Aboelkassem; Kimberly J McCabe; Gary A Huber; Michael Regnier; J Andrew McCammon; Andrew D McCulloch
Journal:  Biophys J       Date:  2019-08-09       Impact factor: 4.033

8.  Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice.

Authors:  Li Wang; Katarzyna Kazmierczak; Chen-Ching Yuan; Sunil Yadav; Masataka Kawai; Danuta Szczesna-Cordary
Journal:  FEBS J       Date:  2017-05-25       Impact factor: 5.542

9.  The Relaxation Properties of Myofibrils Are Compromised by Amino Acids that Stabilize α-Tropomyosin.

Authors:  Beatrice Scellini; Nicoletta Piroddi; Alexander M Matyushenko; Dmitrii I Levitsky; Corrado Poggesi; Sherwin S Lehrer; Chiara Tesi
Journal:  Biophys J       Date:  2017-01-24       Impact factor: 4.033

10.  Energy landscapes reveal the myopathic effects of tropomyosin mutations.

Authors:  Marek Orzechowski; Stefan Fischer; Jeffrey R Moore; William Lehman; Gerrie P Farman
Journal:  Arch Biochem Biophys       Date:  2014-09-18       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.